The gene encoding the human BRCA2 tumour suppressor is mutated in a number of different tumour types, most notably inherited breast cancers. The primary role of BRCA2 is thought to lie in the maintenance of genomic stability via its role in the homologous recombination pathway. We generated mice in which Brca2 was deleted from virtually all cells within the adult small intestine, using a CYP1A1-driven Cre-Lox approach. We noted a significant p53-dependent increase in the levels of spontaneous apoptosis which persisted for several months after removal of the gene and ultimately we observed the spontaneous deletion of Brca2-deficient stem cells. Brca2 deficiency did not lead to gross changes in intestinal physiology but did enhance sensitivity to a variety of DNA crosslinking agents. Taken together, our results indicate that Brca2 plays an important role in the response to DNA damage in the small intestine. Furthermore, we show that Brca2 deficiency results in the spontaneous deletion of stem cells, thereby protecting the small intestine against tumorigenesis.
In humans, inheritance of a single mutated copy of either of the tumour suppressor genes BRCA1 or BRCA2 predisposes to breast cancer, usually after loss of heterozygosity at the second allele (Scully, 2000) . Rarely, inherited mutation of BRCA2 predisposes to cancer in other tissues, most commonly the ovary (The Breast Cancer Linkage Consortium, 1999) . The products of the BRCA1 and BRCA2 genes are large, unrelated proteins, both believed to be independently involved in homologous recombination (HR), a process which allows for the error-free repair of DNA doublestrand breaks (DSBs) (Liu and West, 2002) . BRCA2 is known to participate in this process through its direct interaction with RAD51, the mammalian equivalent of the bacterial RecA protein (Pellegrini et al., 2002) . It is the breakdown in the HR pathway which is believed to be responsible for tumorigenesis in the absence of BRCA2, due to resulting genomic instability (Davies et al., 2001) . Owing to embryonic lethality in mice homozygous for the Brca2-null allele (Ludwig et al., 1997; Sharan et al., 1997; Suzuki et al., 1997) , conditional mutagenesis has been used to study Brca2 function in vivo. Several studies have utilized mammaryspecific promoters to drive Cre-Lox-mediated Brca2 deletion (Jonkers et al., 2001; Ludwig et al., 2001; Cheung et al., 2004) . All resulted in mammary tumours, but only after a long latency and usually with additional deletion or loss of p53 (Jonkers et al., 2001; Ludwig et al., 2001; Cheung et al., 2004) . Brca2 has also been deleted from cells of the developing thymus using an Lck-driven Cre-Lox system, resulting in a p53-dependent increase in the rate of spontaneous apoptosis in activated T cells (Cheung et al., 2002) . These cells showed no significant difference in their apoptotic response to a variety of stimuli, including ionising radiation (IR) (Cheung et al., 2002) . However, several studies have shown that cells lacking fully functional BRCA2, in both humans or mice, do exhibit increased sensitivity to DNA-damaging agents (Sharan et al., 1997; Abbott et al., 1998; Chen et al., 1998; Morimatsu et al., 1998; Patel et al., 1998; D'Andrea and Grompe, 2002; Kraakman-van der Zwet et al., 2002; Donoho et al., 2003) .
The purpose of our study was to analyse the effects of Brca2 deficiency in the murine adult small intestine, a tissue characterized by rapid cell turnover. We utilized a CYP1A1-specific inducible Cre-lox system to efficiently delete the Brca2 gene from crypt cells, including stem cells Sansom et al., 2004) . Our results indicate that Brca2 plays an important role in the response to DNA damage in this tissue, that loss of Brca2 sensitizes crypt cells to apoptosis and that Brca2-deficient stem cells are deleted from the small intestine over time.
To delete Brca2 from cells within the small intestine,
and Ah-cre þ Rosa26R þ Brca2 fl/fl mice were each injected with 80 mg/kg b-napthoflavone over 4 successive days and culled 8 days after the first injection. Recombination at the Rosa26R allele was then used to report the level of Cre-mediated recombination as previously described (Soriano, 1999) . Figure 1 shows representative bgalactosidase-stained small intestinal wholemounts from mice of each genotype, clearly demonstrating efficient recombination in all three backgrounds.
We next characterized the phenotype of the Brca2-deficient small intestine with respect to apoptosis, mitosis and proliferation. As shown in Figure 2a , mice deficient in Brca2 had a significant increase in the number of histologically identified apoptotic bodies (P ¼ 0.004, n ¼ 6; all statistics were performed using a nonparametric Mann-Whitney test with a confidence level of 95%). We also scored apoptosis by counting the number of cells staining positively for the activated form of caspase 3 (Marshman et al., 2001) . The same increase was observed (see Figure 2b ; P ¼ 0.04, n ¼ 3), although the level of caspase 3 positivity was higher than that scored by the histological method. This probably reflects the longer presence of the activated form of caspase 3 as compared to the presence of histologically recognizable apoptotic fragments. This induction of apoptosis at spontaneous levels of DNA damage is presumed to be a direct reflection of failed Brca2-dependent DNA repair.
To determine if this apoptotic phenotype was stable with time, mice were also killed 1, 2, 6 and 14 months Preparation/injection of b-napthoflavone and intestinal wholemount staining was performed as described previously Small intestines were removed immediately following death and flushed with water. Gut rolls were then prepared as described previously . H þ Estained gut roll sections were routinely scored blind for apoptosis by observation at Â 400 magnification. In each experiment, three control and three experimental mice were scored for the number of apoptotic bodies per 25 full crypts. Only intact crypts with a clearly defined cross-section through the lumen were scored. (b) Comparison between scoring apoptosis histologically (open bars) and by staining for the activated form of caspase 3 (closed bars). Immunohistochemical staining for the activated form of caspase 3 was performed as described previously . (c) Representative images of sections stained for the activated form of caspase 3. (d) Graph showing that the apoptotic phenotype in Brca2-deficient small intestines is p53-dependent. In (a), (b) and (d), the y-axis represents the % of apoptotic crypt cells Brca2 deficiency in the murine small intestine T Hay et al after an identical treatment and apoptosis was scored histologically. Figure 2a shows that the level of apoptosis remained high at both 1 month (P ¼ 0.04, n ¼ 3) and 2 months (P ¼ 0.04, n ¼ 3) after Brca2 deletion, but had dropped down to near normal levels at 6 months and back to baseline levels at 14 months, suggesting that Brca2-deficient stem cells may no longer be present at these later timepoints. This possibility is supported by the observation of a mosaic pattern of apoptosis at 6 months, with occasional crypts showing levels of apoptosis comparable with those at earlier timepoints. This again suggests a reduction in the number of Brca2-deficient crypts at this timepoint. There were no signs of any histological lesions at any of the timepoints and no significant differences were observed between control and experimental mice in the levels of mitosis (scored at the same time as apoptosis) or proliferation (assessed by BrdU labelling, as described in Sansom et al., 2004) at any timepoint.
To determine whether the increase in spontaneous apoptosis was p53-dependent, we intercrossed mice carrying the Brca2 fl allele with those carrying the p53-null allele, generating mice homozygous for both alleles (Ah-cre þ Brca2 fl/fl p53
), as well as controls that were heterozygous for the p53-null allele (Ah-cre þ Brca2
). At 8 days after deletion of the Brca2 gene in these mice, we again scored apoptosis (Figure 2d ). Intestines from mice lacking both genes showed wildtype levels of apoptosis compared to mice in which just Brca2 was absent (P ¼ 0.04, n ¼ 3), demonstrating clear p53-dependency. This concurs with the previous observation that p53 is required for the increased levels of spontaneous apoptosis seen in Brca2-deficient activated T cells (Cheung et al., 2002) . The fact that a high percentage of Brca2 mammary tumours in the mouse have lost functional p53 (Ludwig et al., 1997; Sharan et al., 1997; Suzuki et al., 1997) also suggests that p53 may normally be involved in the removal of Brca2-deficient cells from the mammary gland.
As loss of Brca2 has been shown to increase sensitivity to a variety of DNA-damaging agents (Sharan et al., 1997; Abbott et al., 1998; Chen et al., 1998; Morimatsu et al., 1998; Patel et al., 1998; D'Andrea and Grompe, 2002; Kraakman-van der Zwet et al., 2002; Donoho et al., 2003) , we sought to establish whether Brca2-deficient small intestines were altered in their response to such agents. To assess the apoptotic response, mice were injected four times with b-napthoflavone over 4 days and left 8 days before treatment. Figure 3a and b shows the results 6 h after treatment in each case, apart from 5-fluorouracil, whose maximal effect is at 24 h after treatment. There was a significant increase in apoptosis in Brca2-deficient mice with low level mitomycin C (Figure 3a ; P ¼ 0.04, n ¼ 3), but not at a higher dose. For all other agents used, there was no significant difference between control mice and Brca2-deficient mice at either low or high dose. Proliferation was scored by mitosis and BrdU labelling and we found no significant differences following DNA damage. We also determined if clonogenic survival was altered in response to DNA damage (Figure 3c ), using the microcolony assay. We found that clonogenic survival was reduced in the intestines of Brca2-deficient mice after treatment with either 15 mg/kg mitomycin C (P ¼ 0.03, n ¼ 4), 10 mg/kg cisplatin (P ¼ 0.015, n ¼ 4) Figure 3 Brca2-deficient small intestines are sensitized to DNAcrosslinking agents. Apoptotic response to (a) low-and (b) highdose DNA-damaging agents. All of the drugs involved were injected intraperitoneally and were purchased from Sigma, UK, unless stated otherwise. Mitomycin C was dissolved and diluted in water, and injected at a concentration of either 0.1 or 15 mg/kg. Cisplatin (1 mg/ml; Faulding Pharmaceuticals, UK) was injected at 1 or 10 mg/kg. Etoposide was dissolved in dimethylsulphoxide (DMSO), diluted in saline (0.9% NaCl) and injected at 0.5 or 50 mg/kg. N-ethylnitrosourea (ENU) and N-methylnitrosourea (NMNU) were dissolved in DMSO, diluted in saline and injected at 2 or 50 mg/kg. 5-fluorouracil (5-FU; 50 mg/ml; Faulding Pharmaceuticals, UK) was diluted in saline and injected at 40 mg/kg. Mice were killed at 6 h (24 h for 5-FU) post-treatment for analysis of the apoptotic response or 72 h post-treatment for the clonogenic response (see below). Apoptosis was scored as described in the legend to Figure1. (c) Clonogenic response to DNAcrosslinking agents. H þ E-stained gut parcel sections were scored blind for clonogenic survival by observation at Â 200 magnification. A total of 10 intact cross-sections were scored in each mouse for the number of 'live' crypts, defined as having at least six consecutive intact epithelial cells. On average, a cross-section of small intestine contains 125 crypts Brca2 deficiency in the murine small intestine T Hay et al or 15 Gy IR (P ¼ 0.04, n ¼ 3), suggesting that the ability to engage apoptosis does not precisely predict clonogenic survival in response to DNA damage, corroborating previous data for other gene dependancies (Sansom and Clarke, 2002) . Despite the failure to precisely predict long-term survival from the apoptosis data, critically, Brca2-deficiency always reduced clonogenic survival following exposure to DNA damage. Over all, our in vivo data from the small intestine corroborates well, in a physiological setting, the in vitro data, particularly in relation to mitomycin C treatment (Patel et al., 1998; D'Andrea and Grompe, 2002; Kraakmanvan der Zwet et al., 2002; Donoho et al., 2003) .
To further investigate whether loss of the apoptotic phenotype was a reflection of loss of Brca2-deficient stem cells, we injected Ah-cre
fl/fl mice four times over 4 successive days and killed at 2 and 6 months after gene deletion. Figure 4a shows representative fields of bgalactosidase-stained small intestinal wholemounts from both genotypes at these timepoints. No gross difference was observed between the two genotypes at 2 months, although small patches of 'white' unrecombined tissue are present in the homozygotes, in which there are no recombined crypts. At 6 months, the number of recombined clones was reduced in Brca2-deficient intestines. This reduction was confirmed when the percentages of recombined crypts were scored in these mice (Figure 4b ; P ¼ 0.04, n ¼ 3). This result indicates that over time, Brca2-deficient stem cells are deleted and the intestine repopulates with unrecombined cells. This concurs with the timecourse shown in Figure 2a , as the level of apoptosis was reduced at 6 months but not at 2 months. To confirm that the tissue repopulates with cells retaining functional Brca2, we designed a PCR strategy to differentiate between cells containing the unrecombined and recombined loxP-flanked Brca2 alleles (see Figure 4c ). Figure 4d shows PCR results using DNA from blue/white (recombined/unrecombined) and white (unrecombined) tissue samples derived from an Ahcre þ Rosa26R þ Brca2 fl/fl intestine at 6 months after Brca2 deletion. The recombined allele has been lost in the 'white' area of intestine, confirming repopulation with stem cells which carry functional Brca2 protein.
The most likely mechanism for this repopulation is the clonal expansion of cells in which recombination had not taken place, as the overall level of floxing is approximately 90% following four injections of bnapthoflavone. Crypts with wild-type stem cells would be able to expand throughout the remaining tissue by the process of crypt fission (Garcia et al., 1999) , and this would certainly be consistent with the evidence presented in Figure 4a , in which we could see small patches and Ahcre þ Rosa26R þ Brca2 fl/fl mice at 2 and 6 months after deletion of the Brca2 gene. Staining was as described previously . To aid scoring, the intestines have been inverted, so that the villi are pointing downwards and the crypts are nearest to the camera. mice at 2 months. Another possible explanation is that the stem cells were replaced by dormant daughter cells which lie within the same crypt. These cells would presumably be resistant to cre-mediated recombination and must retain a level of 'stemness', which would enable them to revert back to a stem cell phenotype when required (Marshman et al., 2002) .
In conclusion, we show that Brca2 is necessary for the normal response to DNA damage in the murine small intestine. In its absence, cells are directed down a p53-dependent apoptotic pathway. Similarly, we show that Brca2-deficient stem cells are slowly deleted at spontaneous levels of DNA damage, with the tissue returning to a wild-type state by 14 months. From our data, we infer that the deletion of Brca2-deficient cells prevents the future acquisition of mutations which may lead to malignancy. The protracted nature of this deletion contrasts with the rapid repopulation that has been observed following the deletion of other alleles using this approach, most notably b-catenin . In humans, the fact that BRCA2 mutations so rarely give rise to tumours in the small intestine, but do so more frequently in the mammary gland, suggests that BRCA2-null cells are more efficiently removed from the former tissue. Attempts to understand the mechanisms underlying this tissue-specific difference may lead to new rationales for drug design against BRCA2-deficient human tumors.
